ES2051827T3 - Una composicion farmaceutica que contiene aceite de ricino polietoxilado. - Google Patents

Una composicion farmaceutica que contiene aceite de ricino polietoxilado.

Info

Publication number
ES2051827T3
ES2051827T3 ES88200931T ES88200931T ES2051827T3 ES 2051827 T3 ES2051827 T3 ES 2051827T3 ES 88200931 T ES88200931 T ES 88200931T ES 88200931 T ES88200931 T ES 88200931T ES 2051827 T3 ES2051827 T3 ES 2051827T3
Authority
ES
Spain
Prior art keywords
oil
polyetoxilado
ricino
pharmaceutical composition
composition containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88200931T
Other languages
English (en)
Inventor
Jean Mesens
Peer Achiel Paul Van
Jozef Jan Pieter Heykants
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2051827T3 publication Critical patent/ES2051827T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Cardiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Fertilizers (AREA)

Abstract

COMPOSICIONES QUE CONTIENEN FLUNARIZINA COMO INGREDIENTE ACTIVO Y, COMO VEHICULO, UN TENSIOACTIVO APROPIADO. ESTE TENSIOACTIVO ES PREFERENTEMENTE UN ACIDO GRASO O UN ALCOHOL POLIETOXILADO, O UN ACEITE O GRASA (GLICERIDO) POLIETOXILADO Y, MAS ACEITE O GRASA CONTIENE DE 5 A 100 Y, PREFERIBLEMENTE DE 20 A 60 UNIDADES ETOXI Y, SI SE DESEA, OTROS COADYUVANTES.
ES88200931T 1987-05-18 1988-05-10 Una composicion farmaceutica que contiene aceite de ricino polietoxilado. Expired - Lifetime ES2051827T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5064487A 1987-05-18 1987-05-18

Publications (1)

Publication Number Publication Date
ES2051827T3 true ES2051827T3 (es) 1994-07-01

Family

ID=21966482

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88200931T Expired - Lifetime ES2051827T3 (es) 1987-05-18 1988-05-10 Una composicion farmaceutica que contiene aceite de ricino polietoxilado.

Country Status (19)

Country Link
EP (1) EP0292050B1 (es)
JP (1) JPS63303926A (es)
KR (1) KR880013559A (es)
AT (1) ATE69555T1 (es)
AU (1) AU603895B2 (es)
DE (1) DE3866281D1 (es)
DK (1) DK268788A (es)
ES (1) ES2051827T3 (es)
FI (1) FI882307A (es)
GR (1) GR3003482T3 (es)
HU (1) HU199073B (es)
IE (1) IE60937B1 (es)
IL (1) IL86395A (es)
NO (1) NO882134L (es)
NZ (1) NZ224497A (es)
PH (1) PH24425A (es)
PT (1) PT87496B (es)
RU (1) RU1829935C (es)
ZA (1) ZA883492B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532002A (en) * 1989-08-17 1996-07-02 Cortecs Limited Gelatin pharmaceutical formulations
DK0487575T3 (da) * 1989-08-17 1994-11-28 Cortecs Ltd Farmaceutiske formuleringer
NZ258044A (en) * 1992-11-27 1995-12-21 Faulding F H & Co Ltd Pharmaceutical composition comprising taxol, solubilising agent, an acid and an organic solvent
TW401300B (en) * 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
FR2729307B1 (fr) * 1995-01-18 1997-04-18 Seppic Sa Utilisation d'esters d'acides gras ethoxyles comme composants auto-emulsionnables notamment utiles pour la preparation de produits de traitement phytosanitaires ou de medicaments a usage veterinaire ou humain
US6596706B1 (en) * 1997-11-07 2003-07-22 Daiichi Pharmaceutical Co., Ltd. Piperazine-cyclodextrin complexes
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
DE60234952D1 (de) * 2001-09-10 2010-02-11 Tibotec Pharm Ltd VERFAHREN ZUR HERSTELLUNG VON HEXAHYDROFUROc2,3-BÜFURAN-3-OL
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
WO2004062692A1 (en) * 2003-01-13 2004-07-29 Solvay Pharmaceuticals B.V. Formulation of poorly water-soluble active substances
WO2011047259A1 (en) 2009-10-16 2011-04-21 Glaxosmithkline Llc Compositions
CN104069086A (zh) * 2014-07-22 2014-10-01 周有财 一种盐酸氟桂利嗪组合物胶囊及其制备方法
CN113262207B (zh) * 2020-02-17 2022-06-17 正大青春宝药业有限公司 一种盐酸氟桂利嗪胶囊制剂及其制备方法
CN115381791B (zh) * 2022-09-21 2023-06-16 迪沙药业集团有限公司 一种盐酸氟桂利嗪药物组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
EP0151987B1 (de) * 1984-01-28 1991-05-29 Roshdy Dr. Ismail Mittel zur Behandlung von Erkrankungen der Venen und des Analbereichs
DE3421468A1 (de) * 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US5047229A (en) * 1986-12-17 1991-09-10 Miles, Inc. Treatment of cardiovascular and cerebral toxicity using calcium modulators

Also Published As

Publication number Publication date
DE3866281D1 (de) 1992-01-02
PT87496B (pt) 1992-09-30
DK268788A (da) 1988-11-19
AU1613288A (en) 1988-11-24
KR880013559A (ko) 1988-12-21
IE60937B1 (en) 1994-09-07
HUT46851A (en) 1988-12-28
PH24425A (en) 1990-06-25
IL86395A (en) 1992-11-15
HU199073B (en) 1990-01-29
GR3003482T3 (en) 1993-02-17
FI882307A0 (fi) 1988-05-17
IE881477L (en) 1988-11-18
NO882134D0 (no) 1988-05-16
PT87496A (pt) 1989-05-31
EP0292050B1 (en) 1991-11-21
IL86395A0 (en) 1988-11-15
ZA883492B (en) 1990-01-31
JPS63303926A (ja) 1988-12-12
RU1829935C (ru) 1993-07-23
DK268788D0 (da) 1988-05-17
NO882134L (no) 1988-11-21
AU603895B2 (en) 1990-11-29
ATE69555T1 (de) 1991-12-15
NZ224497A (en) 1990-04-26
EP0292050A1 (en) 1988-11-23
FI882307A (fi) 1988-11-19

Similar Documents

Publication Publication Date Title
ES2051827T3 (es) Una composicion farmaceutica que contiene aceite de ricino polietoxilado.
NO940277L (no) Triglycerider og blandinger av slike
MX171861B (es) Composiciones medicinales acuosas que contienen un factor de crecimiento poli-peptidico y el metodo para estabilizar las mismas
ES2040727T3 (es) Un proceso para preparar una formulacion en aerosol en solucion de un analogo.
NZ241876A (en) Pharmaceutical composition comprising a practically water-insoluble cyclic depsipeptide, or other anthelmintic analogues thereof, together with one or more of nonionic surfactants or fats or oils
DE69305328D1 (de) Mikrokapseln mit wänden aus primären alkoholfunktionen enthaltenden polysacchariden, und zusammensetzungen daraus
DK581185D0 (da) Farmaceutisk praeparat indeholdende 13-cis-a-vitaminsyre
ES2061607T3 (es) Capsula de liberacion oral instantanea, con contenido de nifedipina.
ES2148755T3 (es) Formulaciones que contienen leflunomida.
ATE81453T1 (de) Essentielle fettsaeure enthaltende zusammensetzungen.
DK585889D0 (da) Farmaceutisk praeparat
NO891220L (no) Middel som inneholder salicylsyre for behandling av lepidose.
ZA872868B (en) The liquidization of pharmaceutical preparations for filling soft gelatine capsules therewith
ES2062529T3 (es) Uso de alcoholes alifaticos, de c-20 a c-26, para la realizacion de un medicamento destinado al tratamiento de infecciones virales.
DE3778826D1 (de) Bestaendige therapeutische zusammensetzungen, basierend auf hydrophobem pflanzlichem oel und verfahren zu ihrer herstellung.
ES2054029T3 (es) Formulacion de acetato de flecainida con liberacion controlada.
JPS5772908A (en) Removing agent for make-up cosmetic
DE69129232D1 (de) Zusammensetzung aus asphodelus zur erhöhung der anzahl weisser blutzellen
KR910012222A (ko) 화장비누 조성물
KR920019344A (ko) α-리놀렌산을 이용한 간장질환의 예방 및 치료 조성물
IT1207764B (it) Derivati di estere fosforico e composizioni insetticida e acaricida contenenti tali derivati.
KR830003868A (ko) 살충성을 지닌 u.l.v 조성물
KR850002952A (ko) 불안정한 활성성분을 함유한 젤상 외용제의 제조방법

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 292050

Country of ref document: ES